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Background: For phosphate control, patient education is essential due to the limited clearance of phosphate by 
dialysis. However, well-designed randomized controlled trials about dietary and phosphate binder education have 
been scarce.
Methods: We enrolled maintenance hemodialysis patients and randomized them into an education group (n = 48) 
or a control group (n = 22). We assessed the patients’ drug compliance and their knowledge about the phosphate 
binder using a questionnaire.
Results: The primary goal was to increase the number of patients who reached a calcium-phosphorus product of 
lower than 55. In the education group, 36 (75.0%) patients achieved the primary goal, as compared with 16 (72.7%) 
in the control group (P = 0.430). The education increased the proportion of patients who properly took the phosphate 
binder (22.9% vs. 3.5%, P = 0.087), but not to statistical significance. Education did not affect the amount of 
dietary phosphate intake per body weight (education vs. control: -1.18 ± 3.54 vs. -0.88 ± 2.04 mg/kg, P = 0.851). 
However, the dietary phosphate-to-protein ratio tended to be lower in the education group (-0.64 ± 2.04 vs. 0.65 ± 
3.55, P = 0.193). The education on phosphate restriction affected neither the Patient-Generated Subjective Global 
Assessment score (0.17 ± 4.58 vs. -0.86 ± 3.86, P = 0.363) nor the level of dietary protein intake (-0.03 ± 0.33 vs. 
-0.09 ± 0.18, P = 0.569).
Conclusion: Education did not affect the calcium-phosphate product. Education on the proper timing of phosphate 
binder intake and the dietary phosphate-to-protein ratio showed marginal efficacy. 
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Introduction
Hyperphosphatemia is one of the common and serious 
problems that nephrologists encounter when treating 
dialysis patients; it is associated with the development of 
secondary hyperparathyroidism, mineral bone disorder, 
and vascular stiffening and calcification [1,2]. The exact 
mechanisms for these issues are unclear, but several 
studies have reported that serum phosphate stimulates 
transformation of vascular smooth muscle cells into os-
teoblasts. Separately, hyperphosphatemia leads to endo-
thelial dysfunction and elevated fibroblast growth factor 
23, which contributes to left ventricular hypertrophy, 
coronary artery disease, and mortality [3]. Therefore, 
serum phosphate level needs to be maintained in an ade-
quate range. However, only about 50% of dialysis patients 
maintain their phosphate levels within the target range 
of between 3.5 mg/dL and 5.5 mg/dL as suggested by the 
Kidney Disease Outcome Quality Initiative [4].
There are four major ways to manage phosphate level: 
via dialysis, dietary restriction, oral phosphate binders, 
and control of hyperparathyroidism. Phosphorous can 
be partially removed by dialysis; three-times weekly con-
ventional hemodialysis sessions can remove from 300 to 
1,200 mg of phosphorous per session [3,5]. Regular West-
ern diets contain 1,500 mg daily phosphorus, equivalent 
to 10,500 mg per week, so hemodialysis reduces dietary 
phosphate intake to a net of 6,900 mg per week, reflect-
ing the limited efficacy of phosphate removal by dialysis 
[1,5]. To solve this imbalance, phosphate binder is com-
monly used to remove extra phosphorus from the body. 
However, drug compliance is a key for obtaining any 
benefit from phosphate binder because, for optimal ef-
ficacy, the binder must be taken at the correct time, right 
after meals. Therefore, education on dietary phosphate 
restriction and the proper usage of phosphate binder is 
important. However, excessively stringent dietary restric-
tions may lead to malnutrition [2,6-9], so education is 
particularly necessary regarding maintaining good pro-
tein intake with less phosphate. The aim of this study was 
to evaluate the efficacy of education on low-phosphate 
diet and proper phosphate binder intake.
Methods
Patients
This study was a randomized controlled trial conducted 
in a single hospital in Korea from July 2015 to October 
2015. The Consolidated Standards of Reporting Trials 
(CONSORT) study flow is shown in Fig. 1. We assessed 
81 patients who were in maintenance hemodialysis for 
eligibility and excluded 11; nine patients did not meet 
our inclusion criteria, and two refused to participate. We 
included end-stage renal disease patients who had been 
receiving dialysis for more than three months and who 
were older than 18 years of age. Our exclusion criteria 
were as follows: patients with liver cirrhosis; pregnant 
women; patients with alimentary tract malabsorption 
diseases; those with a history of recent alcohol or drug 
abuse; patients receiving chemotherapy for solid organ 
tumor; those with a history of mental illness (e.g., major 
depressive disorder, bipolar disorder, schizophrenia); 
and those who had difficulty in communicating with a 
medical team (e.g., due to dementia, mental retardation).
Study design
We randomized the included patients into an educa-
tion group (n = 48) and a control group (n = 22) after the 
patients were enrolled. We used Stata software version 12 
(Stata Co., College Station, TX, USA) to generate a ran-
dom number for each patient and sorted them into three 
groups; two were intervention groups, and we also ran-
domly allocated patients to one or the other of these by 
blinded random selection. We shared the randomization 
results with the dietitian and the team pharmacist so they 
could provide the education, but the results were con-
cealed from other study investigators. We assessed base-
line medical history, nutritional assessment, and drug 
compliance, with medical history including cause of end-
stage renal disease, Charlson Comorbidity Index score, 
and dialysis vintage. Nutritional assessment entailed Pa-
tient Generated Subjective Global Assessment (PG-SGA) 
score, dietary assessment by three-day recall, handgrip 
power assessment using a handheld dynamometer (JA-
MAR PLUS+; Sammons Preston, Inc., Bolingbrook, IL, 
USA), triceps skin-fold, mid-arm circumference, and bio-
impedance measurements using an Inbody S10 (Inbody, 
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Seoul, Korea). Drug compliance assessment included the 
Morisky Medication Adherence Scale-8 (MMAS-8) and 
a questionnaire designed to assess patients’ knowledge 
regarding proper intake timing of phosphate binder and 
acknowledgement of phosphate binder. The MMAS-8 
was developed to measure adherence to prescribed med-
ications and it has been adequately validated in numer-
ous prior studies [10-12]. 
For this study, center staff collected monthly results for 
numerous laboratory tests (i.e., hemoglobin, albumin, 
total cholesterol, high density lipoprotein cholesterol, 
low density lipoprotein cholesterol, intact parathyroid 
hormone, 25-hydroxy vitamin D, calcium, and phospho-
rus) during the study period. Dietitians and pharma-
cists gave the education group teaching that followed a 
standardized protocol. Each of them had an individual 
meeting with each of the patients in the education group 
at a separate room prepared for the education or at the 
bedside during hemodialysis sessions. The education 
consisted of 30-minute face-to-face education sessions 
with leaflets. After the education, the short-term (at one 
month after education) and long-term (at two or three 
months after education) efficacies were assessed. For 
short-and long-term findings, we assessed the patients’ 
laboratory profiles and their MMAS-8, designed drug 
compliance questionnaire, and PG-SGA scores. To assess 
the effects of the dietary intervention, we repeated three-
day recalls at the short-term assessment one month after 
the patient education sessions. We obtained informed 
consent from all participants and the local institutional 
review boards approved this study (protocol no: AJIRB-
MED-SUR-15-147). The study was performed under Dec-
laration of Helsinki guidelines.
The primary outcome of this study was to increase the 
number of patients who achieved a calcium-phosphate 
product of less than 55. Secondary outcomes of this 
study were as follows: changes in serum phosphate level, 
changes in dietary phosphate intake, change in the di-
etary phosphate-to-protein ratio, change in PG-SGA 
score, change in MMAS-8 score, improvement of pa-
tients’ knowledge about when to take phosphate binder, 
and change in the prescribed bioequivalent dose of 
phosphate binder.
Statistical analysis
Data are presented as means with standard deviations 
for continuous variables and as numbers with percent-
Assessed for eligibility (n = 81)
Randomized (n = 70)




Lost to follow-up (n = 1)
Death (n = 1)
Analyzed (n = 21)
Excluded from analysis (n = 1)
Allocated to intervention (n =
Received allocated intervention (n = 48)
48)
Lost to follow-up (n = 1)
Transplantation (n = 1)
Analyzed (n = 47)
Excluded from analysis (n = 1)
*Event-based individuals were included in the GEE analysis
Excluded (n = 11)
Not meeting inclusion criteria (n = 9)
Declined to participate (n = 2)
Figure 1. Brief diagram of the study. GEE, generalized estimating equation.
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ages for categorical variables. For the cross-sectional 
comparison, we used independent t tests for the continu-
ous variables or chi-squared tests for the categorical vari-
ables as appropriate. Linear mixed models were used for 
the statistical tests of sequential changes of continuous 
variables according to the intervention and generalized 
estimating equations were used for the statistical tests of 
sequential changes in categorical variables. We used P 
for the interactions of intervention and temporal changes 
and considered P < 0.05 to be significant. To determine 
Table 1. Baseline characteristics
Variable Control group (n = 22) Education group (n = 48) Total (n = 70) P value
Demographic characteristic
   Age (yr) 57.3 ± 14.9 59.7 ± 16.4 58.9 ± 15.9 0.562
   Male gender 11 (50.0) 25 (52.1) 36 (51.4) 0.871
   Cause of end-stage renal disease 0.168
      Diabetes mellitus 3 (13.6) 18 (40.0) 21 (31.3)
      Glomerulonephritis 8 (36.4) 7 (15.6) 15 (22.4)
      Hypertension 3 (13.6) 4 (8.9) 7 (10.5)
      Other 1 (4.6) 2 (4.4) 3 (4.5)
      Unknown 7 (31.8) 14 (31.1) 21 (31.3)
   Dialysis vintage (yr) 7.6 ± 7.3 5.1 ± 4.9 5.9 ± 5.9 0.101
Nutritional indices
   Body mass index (kg/m2) 22.1 ± 3.1 22.7 ± 4.0 22.5 ± 3.7 0.577
   Mid-arm muscle circumference (cm) 26.7 ± 3.5 26.5 ± 3.1 26.6 ± 3.2 0.780
   PG-SGA 5.1 ± 3.8 6.6 ± 4.6 6.2 ± 4.4 0.174
   Hand grip strength (kgf) 25.6 ± 12.9 23.4 ± 10.3 24.1 ±11.1 0.464
   nPCR (g/kg/d) 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 0.247
   Caloric intake/ideal body weight (kcal/kg) 24.3 ± 7.5 26.1 ± 6.2 25.6 ± 6.6 0.379
   Carbohydrate intake/ideal body weight (g/kg) 3.6 ± 1.3 3.9 ± 1.0 3.8 ± 1.1 0.485
   Lipid intake/ideal body weight (g/kg) 0.7 ± 0.3 0.7± 0.3 0.7 ± 0.3 0.549
   Protein intake/ideal body weight (g/kg) 1.0 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.239
   Sodium intake/ideal body weight (mg/kg) 60.3 ± 28.4 68.5 ± 25.0 66.3 ± 25.9 0.296
   Potassium intake/ideal body weight (mg/kg) 35.5 ± 13.1 40.4 ± 13.8 39.1 ± 13.6 0.235
   Phosphorus intake/ideal body weight (mg/kg) 13.9 ± 5.3 15.9 ± 4.5 15.4 ± 4.8 0.180
Drug compliance indices
   MMAS-8 score 6.9 ± 1.0 6.4 ± 1.7 6.6 ±1.5 0.147
   Proportion of patients who had poor phosphate control 9 (40.9) 14 (29.7) 23 (32.9) 0.332
   Dosage of phosphate binder* (mg/wk) 7,416 ± 5,698 5,481 ± 3,686 6,089 ± 4,467 0.093
Laboratory values
   Hemoglobin (g/dL) 10.3 ± 1.0 10.3 ± 1.0 10.3 ± 1.0 0.818
   Albumin (g/dL) 3.9 ± 0.2 3.9 ± 0.3 3.9 ± 0.3 0.352
   Phosphorus (mg/dL) 4.6 ± 1.1 4.4 ± 1.4 4.5 ± 1.3 0.614
   Total cholesterol (mg/dL) 143.9 ± 25.5 145.4 ± 30.1 144.9 ± 29.1 0.842
   High-density lipoprotein (mg/dL) 43.8 ± 15.0 43.6 ± 13.4 43.7 ± 13.8 0.962
   Low-density lipoprotein (mg/dL) 78.7 ± 17.8 82.1 ± 27.3 81.0 ± 24.8 0.602
   Intact parathyroid hormone (pg/mL) 274.0 ± 210.4 224.3 ± 172.4 240.0 ± 185.1 0.301
   25-Hydroxy vitamin D (ng/mL) 15.9 ± 6.7 18.3 ± 9.3 17.6 ± 8.6 0.294
   Kt/V 1.6 ± 0.2 1.6 ± 0.2 1.6 ± 0.2 0.598
Data are presented as mean ± standard deviation or number (%). 
Kt/V, volume of plasma cleared of urea divided by the urea distribution volume; MMAS-8, Morisky Medication Adherence Scale-8; nPCR, normalized protein catabolic 
rate; PG-SGA, Patient-Generated Subjective Global Assessment.
*Bioequivalent mg of calcium acetate. 
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sample size, we used 40% as the approximate proportion 
of patients who did not achieve a calcium-phosphate 
product of less than 55 in the control group and we pro-
posed that the intervention would lead to a 75% reduc-
tion (10% uncontrolled calcium-phosphate product in 
the intervention group). We determined the sample size 
of 75 using independent two-proportion comparison 
with 2:1 allocation, 80% power, and 0.05 alpha. We per-




The baseline characteristics of the education group and 
the usual care control group were similar (Table 1). The 
mean age of participants was 58.9 ± 15.9 years and 51.4% 
of the participants were male. Diabetic nephropathy 
(31.3%) was the most common cause of end-stage renal 
disease. The mean MMAS-8 score was 6.6 ± 1.5 and the 
mean PG-SGA score was 6.2 ± 4.4. Mean daily calorie 
intake was 25.6 ± 6.6 kcal/kg. The mean daily protein 
intake by body weight was 1.1 ± 0.3 g/kg. The mean daily 
phosphorus intake by body weight was 15.4 ± 4.8 mg/kg. 
Demographic data, nutritional status, and drug compli-
ance showed no statistical differences. 
Primary outcome
The primary outcome was the number of patients who 
reached the goal of a calcium-phosphate product of 
lower than 55 (Table 2). At the short-term assessment, 
36 (75.0%) patients in the education group achieved the 
primary goal as compared with 16 (72.7%) in the control 
group (P = 0.430). At the long-term assessment (at two 
to three months), both the number and proportion of 
patients who still had a calcium-phosphate product of 
lower than 55 had decreased minimally to 34 (70.8%) in 
the education group and 15 (68.2%) in the control group, 
respectively. 
Effect of low-phosphate dietary education 
Table 3 summarizes the secondary outcomes. For 
serum phosphate levels, we observed no significant 
changes. For dietary phosphate intake, both groups 
showed slightly reduced intakes (P = 0.851). For dietary 
phosphate-to-protein ratio, the education group showed 
a lower ratio, but it did not reach statistical significance 
(P = 0.193). Providing education on phosphate restriction 
did not affect dietary protein intake (P = 0.569) or PG-SGA 
score (P = 0.363).
Effect of pharmacologic education
The MMAS-8 score improved in the education group (P = 
Table 2. Proportions of patients who reached a calcium-phos-
phate product of lower than 55
Calcium-phosphate product < 55 Baseline Short-term Long-term
Control (n = 22) 20 (90.9) 16 (72.7) 15 (68.2)
Intervention (n = 48) 45 (93.8) 36 (75.0) 34 (70.8)
Data are presented as number (%).
Table 3. Secondary outcomes
Variable
Control (n = 22) Education (n = 48)
P value
Baseline Short-term Baseline Short-term
Serum phosphate level 4.6 ± 1.1 5.0 ± 1.1 4.4 ± 1.4 4.7 ± 1.5 0.505
Dietary phosphate intake per ideal body weight (mg/kg) 13.9 ± 5.3 13.3 ± 4.0 15.9 ± 4.5 15.3 ± 5.0 0.851
Dietary phosphate-to-protein ratio 14.2 ± 2.0 15.0 ± 2.1 14.6 ± 1.5 13.9 ± 1.8 0.193
Dietary protein intake per ideal body weight (g/kg) 1.0 ± 0.3 0.9 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.569
PG-SGA 5.1 ± 3.9 4.2 ± 3.0 6.6 ± 4.6 6.8 ± 5.4 0.363
MMAS-8 6.9 ± 1.0 6.9 ± 1.3 6.4 ± 1.7 6.6 ± 1.6 0.445
Proper intake timing of phosphate binder 19 (86.4) 20 (90.9) 31 (64.6) 42 (87.5) 0.087
Acknowledgement of phosphate binder 12 (54.5) 11 (50.0) 29 (60.4) 29 (60.4) 0.698
Bioequivalent dosage of phosphate binder (mg/wk) 7,416 ± 5,698 7,230 ± 4,253 5,481 ± 3,686 6,092 ± 4,462 0.415
Data are presented as mean ± standard deviation or number (%). 
MMAS-8, Morisky Medication Adherence Scale-8; PG-SGA, Patient-Generated Subjective Global Assessment.
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0.445). Education partly increased patients’ knowledge 
of when to take phosphate binder, although it did not 
reach statistical significance (22.9% vs. 3.5%, education 
vs. control, P = 0.087). Additionally, education did not 
increase patients’ acknowledgement of the phosphate 
binder (-4.6% vs. 0%, education vs. control, P = 0.698). 
The weekly bioequivalent phosphate binder dose in the 
control group changed from 7,415.7 ± 5,697.6 mg/wk to 
7,230.1 ± 4,252.6 mg/wk and the dose changed in the ed-
ucation group from 5,481.4 ± 3,685.7 mg/wk to 6,091.5 ± 
4,462.0 mg/wk. The weekly bioequivalent dosage did not 
change significantly between groups (P = 0.415).
Discussion
The primary purpose of this study was to determine 
how many patients could achieve a calcium-phosphate 
product of less than 55 through dietary consultation and 
pharmacological education. After three months, 75.0% 
of patients in the education group achieved the primary 
goal as compared with 72.7% of control group. Meta-
analyses have investigated the percentages of patients 
who reached phosphorus levels of less than 5.5 mg/dL 
after dietary education. Caldeira et al [13] in their meta-
analysis reported that 50% of the education group of 
analyzed studies attained less than 5.5 mg/dL, whereas 
none of the controls were able to reach this goal. In the 
education groups in this meta-analysis, the authors ob-
served a decrease of 0.75 mg/dL in phosphorus levels. In 
another meta-analysis, all of the included studies except 
one reported lower serum phosphorus. The changes in 
phosphorus level ranged from 0.3 to 1.6 mg/dL and eight 
of the studies achieved a serum phosphorus target of 
≤ 5.5 mg/dL after education [14]. We did not observe a 
declining decrement of the phosphorus level following 
the intervention in this study, likely because the serum 
phosphorus was already in the target range before and 
after the study as compared with in the other studies in 
which many patients’ phosphorus levels exceeded 5.5 
mg/dL before the studies [15]. 
Total dietary phosphorous intake did not change after 
the intervention in this study. In other reports, dietary 
nonadherence in patients undergoing maintenance he-
modialysis ranged from 9% to 80.4% [16,17]. It is generally 
known that hemodialysis patients are less likely to adhere 
to dietary phosphate restrictions versus other restrictions 
such as those for sodium or potassium because they are 
less educated about diet itself and the consequences 
of hyperphosphatemia [15,18]. However, of note, in the 
present study, education reduced the dietary phosphate-
to-protein ratio and this lower ratio is important because 
high ratios are related with increased mortality [2]. Low 
ratios are also important because they indicate that the 
patients maintained their overall nutritional statuses 
and dietary protein intake even though they reduced 
their phosphate intake. Therefore, information on the 
phosphate-to-protein ratios in different foods should be 
a mainstay of education [19] so that patients can identify 
foods that have high protein but low phosphorus content 
[7]. In the absence of specific foods, education should fo-
cus on reducing processed foods, which contain inorgan-
ic phosphorus. In a previous report, 46% of hemodialysis 
patients did not know that preservatives that contain 
phosphate are added extensively to processed foods and 
only 25% of patients were aware of the presence of phos-
phate in soda [20]. In a previous study, dietitian-led edu-
cation reduced consumption of phosphorus-containing 
food additives [21], while another study showed that re-
ducing the intake of processed food was one of the most 
effective ways of controlling hyperphosphatemia [17]. 
Education in this study increased patients’ knowledge 
of when to take phosphate binder, although the increase 
was not statistically significant. Notably, the absolute per-
centage of patients who showed better knowledge after 
education was higher in the education group. However, 
as Reddy et al [15] and Elliott et al [18] found, improving 
patient knowledge did not lead to actual changes in mean 
serum phosphate levels. In a study that investigated pa-
tients’ pill-taking habits, only 50% of the patients took 
phosphate binders correctly [16]. Separately, because 
there is a high demand for more information about phos-
phate binders [22], proper education should be provided 
to those who need and want it. 
Pharmacologic education did not change the MMAS-
8 score. Poor adherence to phosphate binder use and 
dietary restrictions is relatively common among mainte-
nance hemodialysis patients [5]. Several studies revealed 
that overall medication nonadherence in these patients 
ranges from 9.7% to 49.5% and that as many as 87% of 
patients have reported not adhering to their phosphate 
binder prescriptions [16,17]. Many factors cause this poor 
adherence. Patients’ ethnic backgrounds, education lev-
els, subjective health statuses, and beliefs about whether 
they even need the phosphate binder, along with the 
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complexity of some patients’ pharmaceutical regimens, 
influence their adherence [6,18]. Separately, hemodialy-
sis patients face large pill burdens that primarily com-
prise phosphate binders. The median number of pills 
per day for hemodialysis patients in the United States is 
19 and phosphate binders account for nearly half of that 
daily burden [23]. Another cause is forgetfulness; in an-
other study, 64% of survey respondents did not take their 
pills as prescribed because they forgot, while 35% did not 
do so because of financial issues [5]. Some reasons for 
poor adherence can be modified through education, but 
some cannot.
There are several limitations in this study. First, our 
study was small and designed to detect a 75% reduction 
in the number of patients with a calcium-phosphate 
product of more than 55, which we did not achieve. 
Second, because we conducted our investigation in a 
single hemodialysis unit, information might have been 
transferred between the two groups, which might have 
reduced the differences between the educated and non-
educated groups. Third, food labels in Korea lack infor-
mation on phosphate content, which might hinder the 
efficacy of phosphate restriction education. Fourth, the 
intervention group was offered education only a single 
time and, finally, we assessed nutritional status based on 
dietary recall, which could have underestimated actual 
intake and inevitably has a wide range of variability [9]. 
In the present study, education did not improve cal-
cium-phosphate product. However, education partly 
corrected proper timing of phosphate binder intake and 
partly lowered the phosphate-to-protein ratio from di-
etary intake, in spite of statistical insignificance. These 
findings imply the importance of continuous and indi-
vidualized educational efforts to reduce serum phospho-
rus levels.
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